Filing Scope and Business Context
The supplied filing is Enochian BioSciences, Inc.’s Form 10-K for the fiscal year ended June 30, 2019, filed September 27, 2019. It does not correspond to the requested company name “Lunai Bioworks Inc.” or the stated “2018 Q4” period. Enochian was a preclinical biotechnology company developing genetically modified cellular and immune therapies for HIV/AIDS and cancer.
The company had eight full-time employees at June 30, 2019. Its principal programs included ENOB-HV-01 for HIV, ENOB-HV-11 and ENOB-HV-12 for preventive and therapeutic HIV vaccines, and several dendritic-cell cancer vaccine programs. No product had been approved or commercialized.
Financial Performance and Liquidity
| Metric | Fiscal 2019 | Fiscal 2018, revised |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $10.99 million | $5.33 million |
| Loss from operations | $(10.99) million | $(5.33) million |
| Net loss | $(18.02) million | $(6.31) million |
| Basic and diluted loss per share | $(0.48) | $(0.29) |
| Net cash used in operating activities | $(8.51) million | $(4.34) million |
| Net cash used in investing activities | $(0.72) million | $(0.58) million |
| Net cash provided by financing activities | $6.02 million | $16.71 million |
| Cash and cash equivalents | $12.28 million | $15.60 million |
| Working capital | $11.38 million | $14.89 million |
Fiscal 2019 general and administrative expense was $8.27 million, research and development expense was $2.50 million, depreciation and amortization was $71,709, and consulting expense was $148,676. Non-cash stock-based compensation was approximately $2.12 million.
Operating and gross margins are not meaningful because the company reported no revenue. The filing does not present conventional funded debt; current liabilities were $1.11 million and the principal non-current liability was contingent consideration of $5.67 million. Total liabilities were $6.78 million and stockholders’ equity was $173.10 million at June 30, 2019.
Cash decreased by $3.32 million during fiscal 2019. Financing cash flow consisted principally of $6.02 million from warrant exercises. Management stated that available cash was expected to fund planned operations for at least twelve months from issuance of the financial statements, but additional capital may be required for research, equipment, IND preparation, and potential acquisitions.
Material Changes Versus the Prior Comparable Period
- Operating expenses increased 106.2% to $10.99 million, primarily from higher general and administrative and research and development spending.
- General and administrative expense increased 112.1% to $8.27 million, including higher non-cash compensation, salaries, security expense, legal, office, and other corporate costs.
- Research and development expense increased 304.9% to $2.50 million, including $1.50 million of R&D consulting fees and increased preclinical activity for the HIV programs.
- Net loss increased 185.4% to $18.02 million. The increase included a $7.07 million unfavorable change in the fair value of contingent consideration, compared with $1.38 million in fiscal 2018.
- Operating cash burn increased 96.1% to $8.51 million, while cash declined 21.3% to $12.28 million.
- The company raised no private-placement proceeds in fiscal 2019, compared with $13.42 million in fiscal 2018, but received $6.02 million from warrant exercises.
- Common shares outstanding increased from 36.16 million to 45.27 million during the fiscal year. An additional 500,000 shares were issued upon option exercise on July 3, 2019.
- The company revised fiscal 2018 financial statements to reclassify acquired in-process research and development assets as indefinite-lived intangible assets. The revision reduced reported fiscal 2018 net loss by $2.84 million and increased indefinite-lived intangible assets by the same amount.
Outlook, Risks, Contingencies, and Unusual Items
Management expected continuing operating losses for at least several years and did not expect meaningful revenue until products were approved for marketing. ENOB-HV-01 was undergoing additional in vivo and in vitro studies intended to support an FDA INTERACT meeting request in early calendar 2020. In vivo work on ENOB-HV-11 and ENOB-HV-12 was expected to begin in early calendar 2020.
- Product candidates remained preclinical and required substantial additional research, regulatory review, clinical trials, manufacturing development, and commercialization work.
- Additional financing may be necessary. Management warned that equity or debt financing may not be available on acceptable terms or at all.
- The company relied on contract manufacturers and academic and scientific collaborators, including Scripps and Fred Hutchinson Cancer Center.
- Competition included larger and better-funded biotechnology and pharmaceutical companies developing gene therapies, cell therapies, cancer vaccines, checkpoint inhibitors, CAR-T products, and related technologies.
- Regulatory approval, clinical safety and efficacy, manufacturing compliance, market acceptance, reimbursement, and intellectual-property protection were identified as significant uncertainties.
- The company reported no material pending legal proceedings and no off-balance-sheet arrangements.
- Related-party arrangements included $1.50 million paid to G-Tech Bio, an entity controlled by members of significant shareholder Weird Science, for R&D consulting services during fiscal 2019.
- The company reported material weaknesses in disclosure controls and internal control over financial reporting, citing limited accounting resources and inadequate segregation of duties. The auditor did not provide an attestation opinion on internal controls because the company qualified for the applicable smaller-reporting-company exemption.
- Indefinite-lived license and goodwill assets totaled approximately $166.46 million and were not impaired under management’s fiscal 2019 assessment. Their recoverability depends heavily on the future success of preclinical programs.
Investor Verification Priorities
- Verify the issuer and reporting period, because the supplied filing is for Enochian BioSciences, Inc. and fiscal 2019 rather than Lunai Bioworks Inc. and 2018 Q4.
- Reconcile cash runway and projected operating burn against the $12.28 million cash balance and $8.51 million fiscal 2019 operating cash outflow.
- Review the terms, valuation assumptions, and potential dilution associated with the $5.67 million contingent consideration liability and remaining contingent shares.
- Assess the substantial concentration of assets in the $154.82 million HIV license and $11.64 million goodwill, including impairment risk.
- Evaluate the status and results of ENOB-HV-01, ENOB-HV-11, ENOB-HV-12, and the cancer programs, including progress toward FDA meetings and IND filings.
- Review related-party consulting arrangements, particularly the $1.50 million G-Tech payment and the underlying services and contractual terms.
- Monitor remediation of the reported material weaknesses in disclosure controls and internal control over financial reporting.
- Consider future equity issuance, warrant exercises, option exercises, and associated dilution, including the 1.94 million contingently issuable shares reported at June 30, 2019.